Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval of Anktiva in combination with BCG.
作者信息
Khattak Aimal Alam, Javed Ahmed, Pokhrel Prakriti, Mukhtar Sameen
机构信息
Department of Internal Medicine, Ayub Medical College, Abbottabad, Pakistan.
Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal.
出版信息
Ann Med Surg (Lond). 2025 Jan 31;87(2):457-459. doi: 10.1097/MS9.0000000000002938. eCollection 2025 Feb.
Abstract
摘要
相似文献
1
Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval of Anktiva in combination with BCG.非肌肉浸润性膀胱癌（NMIBC）治疗的变革：美国食品药品监督管理局（FDA）批准安克替瓦（Anktiva）与卡介苗（BCG）联合使用。
Ann Med Surg (Lond). 2025 Jan 31;87(2):457-459. doi: 10.1097/MS9.0000000000002938. eCollection 2025 Feb.
2
N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review.N-803 联合卡介苗治疗卡介苗初治或无应答的非肌层浸润性膀胱癌：通俗易懂的综述。
Future Oncol. 2024;20(31):2307-2317. doi: 10.1080/14796694.2024.2363744. Epub 2024 Jul 2.
3
Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024.高危卡介苗无反应性非肌肉浸润性膀胱癌给药策略的最新进展：2018年至2024年简要综述
Pharmaceutics. 2024 Aug 30;16(9):1154. doi: 10.3390/pharmaceutics16091154.
4
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.非肌肉浸润性膀胱癌治疗的新视角：免疫检查点抑制剂及其他。
Cells. 2022 Jan 21;11(3):357. doi: 10.3390/cells11030357.
5
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.CREST 研究：sasanlimab 联合卡介苗治疗卡介苗初治高危非肌层浸润性膀胱癌患者的 III 期临床研究。
Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8.
6
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.评估卡介苗膀胱灌注与根治性膀胱切除术对英国高危非肌层浸润性膀胱癌患者的成本效益。
J Med Econ. 2023 Jan-Dec;26(1):411-421. doi: 10.1080/13696998.2023.2189860.
7
Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.用于 BCG 无应答的高危非肌肉浸润性膀胱癌的新型免疫治疗选择。
Cancer Med. 2023 Dec;12(24):21944-21968. doi: 10.1002/cam4.6768. Epub 2023 Dec 1.
8
Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.卡介苗无应答非肌肉浸润性膀胱癌的新兴治疗选择。
Curr Opin Support Palliat Care. 2022 Mar 1;16(1):48-53. doi: 10.1097/SPC.0000000000000587.
9
A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.一种非肌肉浸润性膀胱癌的多基因标志物可识别对包括卡介苗和免疫检查点抑制剂在内的免疫疗法有反应的患者。
Int J Mol Sci. 2024 Mar 28;25(7):3800. doi: 10.3390/ijms25073800.
10
Current advances in BCG-unresponsive non-muscle invasive bladder cancer.BCG 无应答性非肌肉浸润性膀胱癌的最新进展。
Expert Opin Investig Drugs. 2019 Sep;28(9):757-770. doi: 10.1080/13543784.2019.1655730. Epub 2019 Aug 15.
引用本文的文献
1
Prospective Analysis of Residual Urine Volume and Its Association With Intravesical Recurrence in Patients With Non-Muscle-Invasive Bladder Cancer.非肌层浸润性膀胱癌患者残余尿量的前瞻性分析及其与膀胱内复发的关联
Cureus. 2025 May 13;17(5):e84023. doi: 10.7759/cureus.84023. eCollection 2025 May.
本文引用的文献
1
In brief: Anktiva for bladder cancer.简而言之：用于膀胱癌的Anktiva。
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-e106. doi: 10.58347/tml.2024.1705e.
2
Advances in diagnosis and treatment of bladder cancer.膀胱癌的诊断与治疗进展。
BMJ. 2024 Feb 12;384:e076743. doi: 10.1136/bmj-2023-076743.
3
Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer.N-803 联合卡介苗治疗卡介苗无应答性非肌肉浸润性膀胱癌的 2/3 期试验中的生活质量。
Urol Pract. 2024 Mar;11(2):367-375. doi: 10.1097/UPJ.0000000000000517. Epub 2024 Jan 16.
4
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌（Ta、T1和原位癌）指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
5
Treatment of muscle-invasive and advanced bladder cancer in 2020.2020 年肌层浸润性和晚期膀胱癌的治疗。
CA Cancer J Clin. 2020 Sep;70(5):404-423. doi: 10.3322/caac.21631. Epub 2020 Aug 7.
6
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.性别与膀胱癌：病因、生物学和结局的协作综述。
Eur Urol. 2016 Feb;69(2):300-10. doi: 10.1016/j.eururo.2015.08.037. Epub 2015 Sep 4.
7
Epidemiology and risk factors of urothelial bladder cancer.尿路上皮膀胱癌的流行病学和危险因素。
Eur Urol. 2013 Feb;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033. Epub 2012 Jul 25.
Zotero 插件